• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas

byKassandra McFarlaneandSze Wah Samuel Chan
December 1, 2021
in Neurology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Response to treatment was noted in 33% of the high-grade glioma cohort and 69% of the low-grade cohort.

2. The most common adverse event in all patients was fatigue.

Evidence Rating Level: 2 (Good)

Study Rundown: Glioblastoma is notably difficult to treat as it is resistant to many therapies. The BRAF inhibitor dabrafenib has been previously shown to have clinical effect in pediatric patients with BRAF mutation-positive glioma. Multiple tumour types have been shown to respond to a dual-combination of dabrafenib and trametinib (a MEK inhibitor). This study explored the outcome on disease response rate, progression-free survival (PFS), overall survival (OS), and safety in adult patients with BRAF mutation-positive high- or low-grade glioma receiving dabrafenib plus trametinib. 33% of patients in the high-grade glioma cohort had an objective response rate, and 69% had a response in the low-grade cohort. In the high-grade glioma cohort, median PFS determined by independent radiology review was 4.5 months, and was 14 months for the low-grade cohort. OS in the high-grade cohort was 17.6 months and was not reached in the low-grade group. The most common adverse event experienced among both groups was fatigue, followed by headache, nausea, and pyrexia. Limitations to this study include the lack of a control group for comparison and a lack of in-depth questionnaire for neurological symptoms. Overall, patients with BRAF mutation-positive high- or low-grade glioma may benefit from treatment with dabrafenib plus trametinib.

Click to read the study in The Lancet Oncology

Click to read an accompanying editorial in The Lancet Oncology

RELATED REPORTS

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

Relevant Reading: BRAF mutation marks out specific subgroups of glioma

In-Depth [randomized controlled trial]: This single-arm, phase 2 study conducted out of multiple centres internationally recruited adult patients with BRAF mutation-positive glioma and separated them into a high-grade cohort (45 patients) or low-grade cohort (13 patients). Patients in the high-grade cohort were required to have measurable disease at baseline in addition to having previously received either radiotherapy, chemotherapy, or both. Those with low-grade glioma were required to have measurable disease at baseline. Objective response rate was the primary outcome, with progression-free survival (PFS), overall survival (OS), and safety being secondary outcomes. An objective response rate was noted in 33% of the high-grade cohort (95% confidence interval (CI), 20-49%). In the low-grade cohort a response rate of 69% was reported (95% CI, 39-91%). Median PFS by independent radiology review was 4.5 months (95% CI, 1.8-7.4 months) in the high-grade cohort, and 14 months (95% CI, 4.7-46.9 months) in the low-grade cohort. OS was 17.6 months (95% CI, 9.5-45.2 months) in the high-grade cohort and not reached in the low-grade cohort (95% CI, 11.6 to not reached). Adverse events were common, with 93% of the total study population experiencing them (47% of the high-grade group, 61% of the low-grade group). 50% of all patients (both cohorts) experienced fatigue, 43% had headache, 34% had nausea, and 33% had pyrexia. Dose reductions were noted in 38% of all patients, interruptions in 41%, and complete termination of treatment in 9% of all patients due to adverse events. Serious adverse events were reported in 33% of the high-grade cohort, the most frequent being seizures. Serious adverse events were found in 23% of the low-grade cohort, the most frequent being pyrexia.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BRAF inhibitorgliomaMEK inhibitor
Previous Post

177Lu-Dotatate plus octreotide was not superior in overall survival compared to octreotide alone for neuroendocrine tumours

Next Post

COVID-19 shutdown may have decreased gambling rates in Australia

RelatedReports

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
StudyGraphics

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

August 25, 2023
Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]
Oncology

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

August 21, 2023
#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy
StudyGraphics

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

June 10, 2021
Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy
Hematology

Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia

June 7, 2021
Next Post
Casino expansion associated with decreased childhood risk of obesity

COVID-19 shutdown may have decreased gambling rates in Australia

Risk score aids in identifying spermicide failure

Logistical barriers may impact access to contraceptive use amongst females with opioid use disorder

Geriatric assessment and management may reduce adverse events in older cancer patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mepolizumab decreases exacerbations in patients with eosinophilic COPD
  • Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis
  • #VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.